American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works

Energy Metabolism in the Liver

Rui, L. (2014) · Comprehensive physiology · doi:10.1002/cphy.c130024 · Cited by 2,258 · see citing works

Hyperglycemic crises in adult patients with diabetes

Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062 · see citing works

Fuel Metabolism in Starvation

Cahill, G. F. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111258 · Cited by 1,318 · see citing works

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry

Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · see citing works

Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition

Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849 · see citing works

Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors

Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · see citing works

American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan – 2015 — Executive Summary

Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G. E., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S. E., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 631 · see citing works

Active sugar transport in health and disease

Wright, E. M., Hirayama, B. A., & Loo, D. F. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01746.x · Cited by 627 · see citing works

Efficacy and Safety of Low-Carbohydrate Diets: A Systematic Review

Bravata, D. M., Sanders, L., Huang, J., Krumholz, H. M., Olkin, I., Gardner, C. D., & Bravata, D. M. (2003) · JAMA · doi:10.1001/jama.289.14.1837 · Cited by 561 · see citing works

American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559 · see citing works

Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo.

Cherrington, A. D. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1198 · Cited by 500 · see citing works

SGLT inhibitors in management of diabetes

Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70050-0 · Cited by 333 · see citing works

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

Erondu, N., Desai, M. G., Ways, K., & Meininger, G. E. (2015) · Diabetes Care · doi:10.2337/dc15-1251 · Cited by 324 · see citing works

Euglycaemic Diabetic Ketoacidosis

Munro, J., Campbell, I. W., McCuish, A. C., & Duncan, L. J. P. (1973) · BMJ · doi:10.1136/bmj.2.5866.578 · Cited by 322 · see citing works

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors

Ogawa, W., & Sakaguchi, K. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12401 · Cited by 307 · see citing works

Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

Henry, R. R., Thakkar, P., Tong, C., Polidori, D., & Alba, M. (2015) · Diabetes Care · doi:10.2337/dc15-1730 · Cited by 286 · see citing works

Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Henry, R. R., Rosenstock, J., Edelman, S. V., Mudaliar, S. R., Chalamandaris, A.-G., Kasichayanula, S., Bogle, A., Iqbal, N., List, J. F., & Griffen, S. C. (2014) · Diabetes Care · doi:10.2337/dc13-2955 · Cited by 238 · see citing works

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

Perkins, B. A., Cherney, D. Z. I., Partridge, H., Soleymanlou, N., Menezes, H. T., Zinman, B., Fagan, N. M., Kaspers, S., Woerle, H., Broedl, U. C., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2338 · Cited by 232 · see citing works

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

Sands, A., Zambrowicz, B., Rosenstock, J., Lapuerta, P., Bode, B. W., Garg, S. K., Buse, J. B., Banks, P. L., Heptulla, R. A., Rendell, M., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2806 · Cited by 216 · see citing works

Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet‐Induced Obese (DIO) Rats

Devenny, J. J., Godonis, H. E., Harvey, S. J., Rooney, S., Cullen, M. J., & Pelleymounter, M. A. (2012) · Obesity · doi:10.1038/oby.2012.59 · Cited by 212 · see citing works

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study

Kaku, K., Watada, H., Iwamoto, Y., Utsunomiya, K., Terauchi, Y., Tobe, K., Tanizawa, Y., Araki, E., Ueda, M., Suganami, H., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-65 · Cited by 212 · see citing works

Stimulation of Lipolysis in Humans by Physiological Hypercortisolemia

Divertie, G. D., Jensen, M. D., & Miles, J. M. (1991) · Diabetes · doi:10.2337/diab.40.10.1228 · Cited by 201 · see citing works

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

Yokono, M., Takasu, T., Hayashizaki, Y., Mitsuoka, K., Kihara, R., Muramatsu, Y., Miyoshi, S., Tahara, A., Kurosaki, E., Li, Q., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.040 · Cited by 195 · see citing works

Can Serum β-Hydroxybutyrate Be Used to Diagnose Diabetic Ketoacidosis?

Sheikh‐Ali, M., Karon, B. S., Basu, A., Kudva, Y. C., Muller, L. A., Xu, J., Schwenk, W. F., & Miles, J. M. (2008) · Diabetes Care · doi:10.2337/dc07-1683 · Cited by 177 · see citing works

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial ( EASE ‐1)

Pieber, T. R., Famulla, S., Eilbracht, J., Cescutti, J., Soleymanlou, N., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Kaspers, S. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12494 · Cited by 167 · see citing works

Hospital admission for diabetic ketoacidosis or severe hypoglycemia in 31,330 young patients with type 1 diabetes

Karges, B., Rosenbauer, J., Holterhus, P.-M., Beyer, P., Seithe, H., Vogel, C., Böckmann, A., Peters, D., Müther, S., Neu, A., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0129 · Cited by 129 · see citing works

Ketoacidosis occurs in both Type 1 and Type 2 diabetes— a population‐based study from Northern Sweden

Wang, Z. H., Selstam, E. K., & Eriksson, J. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02461.x · Cited by 120 · see citing works

Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet

Hayami, T., Kato, Y., Kamiya, H., Kondo, M., Naito, E., Sugiura, Y., Kojima, C., Sato, S., Yamada, Y., Kasagi, R., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12330 · Cited by 115 · see citing works

Ketoacidosis during a Low-Carbohydrate Diet

Shah, P., & Isley, W. L. (2006) · New England Journal of Medicine · doi:10.1056/nejmc052709 · Cited by 95 · see citing works

Renal conservation of ketone bodies during starvation

SAPIR, D. G., & Owen, O. E. (1975) · Metabolism · doi:10.1016/0026-0495(75)90004-9 · Cited by 92 · see citing works

Renal Tubular Reabsorption of Acetoacetate, Inorganic Sulfate and Inorganic Phosphate in the Dog as Affected by Glucose and Phlorizin

Cohen, J. J., Berglund, F., & Lotspeich, W. D. (1955) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1955.184.1.91 · Cited by 78 · see citing works

SGLT inhibition and euglycaemic diabetic ketoacidosis

Hine, J. L., Paterson, H., Abrol, E., Russell-Jones, D. L., & Herring, R. A. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00204-1 · Cited by 77 · see citing works

Differential effects of fasting and dehydration in the pathogenesis of diabetic ketoacidosis.

Burge, M., García, N., Qualls, C., & Schade, D. (2001) · Metabolism: Clinical and Experimental · doi:10.1053/meta.2001.20194 · Cited by 72 · see citing works

Diabetic ketoacidosis in Denmark: epidemiology, incidence rates, precipitating factors and mortality rates

Nørgaard, K., Eskildsen, P. C., Vadstrup, S., & Nerup, J. (1989) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1989.tb01384.x · Cited by 64 · see citing works

Effects of pulsatile delivery of basal growth hormone on lipolysis in humans

Cersósimo, E., Danou, F. N., Persson, M., & Miles, J. M. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.1.e123 · Cited by 55 · see citing works

Toxigenic and Metabolic Causes of Ketosis and Ketoacidotic Syndromes

Cartwright, M. M., Hajja, W., Al-Khatib, S., Hazegh-Azam, M., Sreedhar, D., Li, R. N., Wong-Mckinstry, E., & Carlson, R. W. (2012) · Critical Care Clinics · doi:10.1016/j.ccc.2012.07.001 · Cited by 40 · see citing works

Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium–Glucose Cotransporter 2 Inhibitor Treatment

Storgaard, H., Bagger, J. I., Knop, F. K., Vilsbøll, T., & Rungby, J. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12457 · Cited by 39 · see citing works

Stimulatory effect of norepinephrine on ketogenesis in normal and insulin-deficient humans

Keller, U. B., Gerber, P. P., & Stauffacher, W. (1984) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1984.247.6.e732 · Cited by 36 · see citing works

Effect of Epinephrine and Somatostatin-induced Insulin Deficiency on Ketone Body Kinetics and Lipolysis in Man

Weiss, M., Keller, U. B., & Stauffacher, W. (1984) · Diabetes · doi:10.2337/diab.33.8.738 · Cited by 34 · see citing works

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus

Tamez, H. E., Tamez, A. L., Garza‐Garza, L. A., Hernandez, M. I., & Polanco, A. C. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0210-x · Cited by 34 · see citing works

Acute Intractable Vomiting and Severe Ketoacidosis Secondary to the Dukan Diet©

Freeman, T. F., Willis, B., & Krywko, D. M. (2014) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2014.06.020 · Cited by 20 · see citing works

Renal reabsorption and utilization of hydroxybutyrate and acetoacetate in starved rats

Barac‐Nieto, M. (1986) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1986.251.2.f257 · Cited by 15 · see citing works

Relationship Between Severity of Hyperglycemia and Metabolic Acidosis in Diabetic Ketoacidosis

Brandt, K. R., & MILES, J. M. (1988) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)65501-3 · Cited by 10 · see citing works

Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 874 · see citing works

A practical review of C-peptide testing in diabetes

Leighton, E., Sainsbury, C. A., & Jones, G. C. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0265-4 · Cited by 773 · see citing works

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary

Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598 · see citing works

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

DeFronzo, R. A., Norton, L., & Abdul‐Ghani, M. A. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.170 · Cited by 556 · see citing works

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 499 · see citing works

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435 · see citing works

Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study

Hallberg, S. J., McKenzie, A. L., Williams, P. T., Bhanpuri, N. H., Peters, A. L., Campbell, W. W., Hazbun, T. L., Volk, B. M., McCarter, J. P., Phinney, S. D., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0373-9 · Cited by 406 · see citing works

Effects of sotagliflozin added to insulin in patients with type 1 diabetes

Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417 · see citing works

Perioperative Hyperglycemia Management: An Update

Duggan, E. W., Carlson, K., & Umpierrez, G. E. (2017) · Anesthesiology · doi:10.1097/aln.0000000000001515 · Cited by 402 · see citing works

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

Ueda, P., Svanström, H., Melbye, M., Eliasson, B., Svensson, A., Franzén, S., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2018) · BMJ · doi:10.1136/bmj.k4365 · Cited by 371 · see citing works

SGLT2 Inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis

Goldenberg, R. M., Berard, L. D., Cheng, A. Y. Y., Gilbert, J. D., Verma, S., Woo, V. C., & Yale, J.-F. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.002 · Cited by 354 · see citing works

Emerging role of SGLT-2 inhibitors for the treatment of obesity

Pereira, M. J., & Eriksson, J. W. (2019) · Drugs · doi:10.1007/s40265-019-1057-0 · Cited by 342 · see citing works

Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297 · see citing works

Very-Low-Calorie Ketogenic Diet (VLCKD) in the Management of Metabolic Diseases: Systematic Review and Consensus Statement from the Italian Society of Endocrinology (SIE)

Caprio, M., Infante, M., Moriconi, E., Armani, A., Fabbri, A., Mantovani, G., Mariani, S., Lubrano, C., Poggiogalle, E., Migliaccio, S., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01061-2 · Cited by 283 · see citing works

Low-Carb and Ketogenic Diets in Type 1 and Type 2 Diabetes

Bolla, A. M., Caretto, A., Laurenzi, A., Scavini, M., & Piemonti, L. (2019) · Nutrients · doi:10.3390/nu11050962 · Cited by 226 · see citing works

Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients

French, E. K., Donihi, A. C., & Korytkowski, M. T. (2019) · BMJ · doi:10.1136/bmj.l1114 · Cited by 200 · see citing works

Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review

Thiruvenkatarajan, V., Meyer, E. J., Nanjappa, N., van Wijk, R. M. A. W., & Jesudason, D. R. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.03.028 · Cited by 195 · see citing works

Pharmacotherapy of type 2 diabetes: An update

Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 190 · see citing works

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study

Danne, T., Cariou, B., Banks, P. L., Brändle, M., Brath, H., Franek, E., Kushner, J. A., Lapuerta, P., McGuire, D. K., Peters, A. L., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0342 · Cited by 186 · see citing works

SGLT 2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature

Burke, K. R., Schumacher, C., & Harpe, S. E. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1881 · Cited by 184 · see citing works

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

CEFALO, C. M. A., Cinti, F., Moffa, S., Impronta, F., Sorice, G. P., Mezza, T., Pontecorvi, A., & Giaccari, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0828-y · Cited by 180 · see citing works

Euglycemic diabetic ketoacidosis: A missed diagnosis

Nasa, P., CHAUDHARY, S. K., Shrivastava, P. K., & Singh, A. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i5.514 · Cited by 165 · see citing works

Management of Inpatient Hyperglycemia and Diabetes in Older Adults

Umpierrez, G. E., & Pasquel, F. J. (2017) · Diabetes Care · doi:10.2337/dc16-0989 · Cited by 170 · see citing works

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

Jabbour, S. A., Seufert, J., Scheen, A. J., Bailey, C. J., Karup, C., & Langkilde, A. M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13124 · Cited by 157 · see citing works

Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes

Ehrmann, D., Kulzer, B., Roos, T., Haak, T., Al-Khatib, M., & Hermanns, N. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30042-5 · Cited by 141 · see citing works

SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission

Hamblin, P. S., Wong, R., Ekinci, E. I., Fourlanos, S., Shah, S., Jones, A. R., Hare, M. J. L., Calder, G. L., Epa, D. S., George, E. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00139 · Cited by 126 · see citing works

Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management

Long, B., Lentz, S., Koyfman, A., & Gottlieb, M. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.02.015 · Cited by 150 · see citing works

Blood Ketones: Measurement, Interpretation, Limitations, and Utility in the Management of Diabetic Ketoacidosis

Dhatariya, K. (2016) · The Review of Diabetic Studies · doi:10.1900/rds.2016.13.217 · Cited by 121 · see citing works

Sodium‐glucose co‐transporter‐2 inhibitors and diabetic ketoacidosis: <scp>A</scp> n updated review of the literature

Bonora, B. M., Avogaro, A., & Fadini, G. P. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13012 · Cited by 118 · see citing works

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies

Thrasher, J. R. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.009 · Cited by 113 · see citing works

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies

Thrasher, J. R. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.004 · Cited by 112 · see citing works

SGLT2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications

Meyer, E. J., Gabb, G. M., & Jesudason, D. R. (2018) · Diabetes Care · doi:10.2337/dc17-1721 · Cited by 110 · see citing works

Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: A STICH protocol

Garg, S. K., Peters, A. L., Buse, J. B., & Danne, T. (2018) · Diabetes Technology &amp; Therapeutics · doi:10.1089/dia.2018.0246 · Cited by 108 · see citing works

Diabetic ketoacidosis with SGLT2 inhibitors

Musso, G., Saba, F., Cassader, M., & Gambino, R. (2020) · BMJ · doi:10.1136/bmj.m4147 · Cited by 104 · see citing works

Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature

Diaz-Ramos, A., Eilbert, W. P., & Marquez, D. (2019) · International Journal of Emergency Medicine · doi:10.1186/s12245-019-0240-0 · Cited by 98 · see citing works

The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis

Chen, J., Fan, F., Wang, J. Y., Long, Y., Gao, C., Stanton, R. C., & Xu, Y. (2017) · Scientific Reports · doi:10.1038/srep44128 · Cited by 91 · see citing works

Sodium‐glucose co‐transporter type‐2 inhibitors: pharmacology and peri‐operative considerations

Milder, D. A., Milder, T. Y., & Kam, P. C. A. (2018) · Anaesthesia · doi:10.1111/anae.14251 · Cited by 91 · see citing works

Diabetic ketoacidosis

Calimag, A. P. P., Chlebek, S., Lerma, E. V., & Chaiban, J. T. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101418 · Cited by 91 · see citing works

DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 93 · see citing works

Diagnóstico e Tratamento da Cetoacidose Diabética Euglicêmica

Santomauro, A. T. M. G., Junior, A. C. S., Raduan, R. A., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-22 · Cited by 82 · see citing works

SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes

Donnan, K., & Segar, L. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.01.002 · Cited by 76 · see citing works

Euglycemic Ketoacidosis

Bonora, B. M., Avogaro, A., & Fadini, G. P. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01307-x · Cited by 72 · see citing works

SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report

Wang, K. M., & Isom, R. T. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2019.12.006 · Cited by 67 · see citing works

Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State

Gosmanov, A. R., Gosmanova, E. O., & Kitabchi, A. E. (2021) · Cited by 65 · see citing works

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64 · see citing works

Ketones: the double-edged sword of SGLT2 inhibitors?

Lupsa, B. C., Kibbey, R. G., & Inzucchi, S. E. (2022) · Diabetologia · doi:10.1007/s00125-022-05815-1 · Cited by 66 · see citing works

Ketoacidosis and SGLT2 Inhibitors: A Narrative Review

Morace, C., Lorello, G., Bellone, F., Quartarone, C., Ruggeri, D., Giandalia, A., Mandraffino, G., Minutoli, L., Squadrito, G., Russo, G. T., et al. (2024) · Metabolites · doi:10.3390/metabo14050264 · Cited by 63 · see citing works

Euglycemic Diabetic Ketoacidosis and Sodium-Glucose Cotransporter-2 Inhibitors: A Focused Review of Pathophysiology, Risk Factors, and Triggers

Somagutta, M. K. R., Agadi, K., Hange, N., Jain, M. S., Batti, E., Emuze, B. O., Amos-Arowoshegbe, E. O., Popescu, S., Hanan, S., Kumar, V. R., et al. (2021) · Cureus · doi:10.7759/cureus.13665 · Cited by 62 · see citing works

The Treatment of Painful Diabetic Neuropathy

SLOAN, G. P., Alam, U., Selvarajah, D., & Tesfaye, S. H. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210707112413 · Cited by 64 · see citing works

Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression

Musso, G., Sircana, A., Saba, F., Cassader, M., & Gambino, R. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003461 · Cited by 61 · see citing works

ISPAD Clinical Practice Consensus Guidelines 2018: Sick day management in children and adolescents with diabetes

Laffel, L. M., Limbert, C., Phelan, H., Virmani, A., Wood, J., & Hofer, S. E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12741 · Cited by 61 · see citing works

Acute Metabolic Emergencies in Diabetes: DKA, HHS and EDKA

Muneer, M. A., & Akbar, I. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_545 · Cited by 57 · see citing works

Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes

Busch, R. S., & Kane, M. P. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1342509 · Cited by 57 · see citing works

Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors

Vitale, R. J., Valtis, Y. K., McDonnell, M. E., Palermo, N. E., & Fisher, N. D. L. (2020) · AACE Clinical Case Reports · doi:10.1016/j.aace.2020.11.019 · Cited by 55 · see citing works

Effect of the Ketogenic Diet on the Prophylaxis and Treatment of Diabetes Mellitus: A Review of the Meta-Analyses and Clinical Trials

Dyńka, D., Kowalcze, K., Ambrożkiewicz, F., & Paziewska, A. (2023) · Nutrients · doi:10.3390/nu15030500 · Cited by 54 · see citing works

Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor

DeFronzo, R. A., CHILTON, R. J., Norton, L., Clarke, G., Ryder, R. E. J., & Abdul‐Ghani, M. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12652 · Cited by 53 · see citing works

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes

Peralta, F. G., Abreu, C., Lecube, A., Bellido, D., Soto, A., Morales, C., Brito-Sanfiel, M. Á., & Umpierrez, G. E. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0277-0 · Cited by 52 · see citing works

Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review

Bamgboye, A. O., Oni, I. O., & Collier, A. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03051-3 · Cited by 48 · see citing works

Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?

Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 51 · see citing works

Coronavirus and Cardiometabolic Syndrome

Mechanick, J. I., Rosenson, R. S., Pinney, S., MANCINI, D. M., Narula, J., & Fuster, V. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.069 · Cited by 50 · see citing works

Glycemic Management in the Operating Room: Screening, Monitoring, Oral Hypoglycemics, and Insulin Therapy

Duggan, E. W., & Chen, Y. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1277-4 · Cited by 49 · see citing works

Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors

Lee, Y., Lim, S. K., & Davies, M. J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01170-4 · Cited by 55 · see citing works

SGLT2 inhibitor/DPP-4 inhibitor combination therapy – complementary mechanisms of action for management of type 2 diabetes mellitus

Dey, J. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1307081 · Cited by 44 · see citing works

Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable

Cosentino, F., Ceriello, A., Baeres, F. M. M., Fioretto, P., Garber, A. J., Stough, W. G., George, J. T., Grant, P. J., Khunti, K., Langkilde, A. M., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy677 · Cited by 45 · see citing works

Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?

Otto-Buczkowska, E., & Jainta, N. (2017) · Intern J Endocrinol Metab · doi:10.5812/ijem.13008 · Cited by 43 · see citing works

Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy—an emerging problem and solutions offered by diabetes technology

Pfützner, A., Klonoff, D. C., Heinemann, L., Ejskjær, N., & Pickup, J. C. (2017) · Endocrine · doi:10.1007/s12020-017-1264-y · Cited by 43 · see citing works

Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease

Milder, T. Y., STOCKER, S. L., Day, R. O., & Greenfield, J. R. (2020) · Drug Safety · doi:10.1007/s40264-020-01010-6 · Cited by 43 · see citing works

Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies

Peters, A. L., McGuire, D. K., Danne, T., Kushner, J. A., Rodbard, H. W., Dhatariya, K., Sawhney, S., Banks, P. L., Jiang, W., Davies, M. J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0924 · Cited by 40 · see citing works

Postoperative outcomes among sodium-glucose cotransporter 2 inhibitor users

Tallarico, R. T., Jing, B., Lu, K., Chawla, S. A., Luo, Y., Badathala, A., Chen, C. L., Wallace, A. W., & Legrand, M. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.0940 · Cited by 40 · see citing works

Non-immunological complications following kidney transplantation

Cohen‐Bucay, A., Gordon, C. E., & Francis, J. M. (2019) · F1000Research · doi:10.12688/f1000research.16627.1 · Cited by 41 · see citing works

Perioperative glycemic management in adults presenting for elective cardiac and non-cardiac surgery

Sreedharan, R., Khanna, S. K., & Shaw, A. (2023) · Perioperative Medicine · doi:10.1186/s13741-023-00302-6 · Cited by 45 · see citing works

Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials

Yang, S., Liu, Y., Zhang, S., Wu, F., Liu, D., Wu, Q., Zheng, H., Fan, P., & Su, N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1145587 · Cited by 37 · see citing works

Euglycemic Diabetic Ketoacidosis in the Setting of SGLT2 Inhibitor Use and Hypertriglyceridemia: A Case Report and Review of Literature

Gajjar, K., & Luthra, P. (2019) · Cureus · doi:10.7759/cureus.4384 · Cited by 35 · see citing works

The use of sodium‐glucose co‐transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?

Koufakis, T., Mustafa, O. G., Ajjan, R., García–Moll, X., Zebekakis, P. E., Dimitriadis, G., & Kotsa, K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13107 · Cited by 35 · see citing works

Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects

da Silva, J. C., Filho, J. D. S. R., Cavalcanti, C. A. J., Martins, A., & Salles, J. E. N. (2020) · Drugs & Aging · doi:10.1007/s40266-020-00757-y · Cited by 35 · see citing works

Efficacy and safety of dapagliflozin over 1 year as add‐on to insulin therapy in J apanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial

Araki, E., Onishi, Y., Asano, M., Kim, H., & Yajima, T. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12853 · Cited by 35 · see citing works

Transcultural Diabetes Care in The United States – A Position Statement by the American Association of Clinical Endocrinologists

Mechanick, J. I., Adams, S., Davidson, J. A., Fergus, I. V., Galindo, R. J., McKinney, K. H., Petak, S. M., Sadhu, A., Samson, S. L., Vedanthan, R., et al. (2019) · Endocrine Practice · doi:10.4158/ps-2019-0080 · Cited by 34 · see citing works

Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus

Carlson, C. J., & Santamarina, M. L. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1216100 · Cited by 33 · see citing works

Sodium-glucose Cotransporter-2 Inhibitors induced euglycemic diabetic ketoacidosis: A meta summary of case reports

Juneja, D., Nasa, P., Jain, R., & Singh, O. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i8.1314 · Cited by 32 · see citing works

The role of SGLT-2 inhibitors in managing type 2 diabetes

Tsushima, Y., Lansang, M. C., & Makin, V. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20088 · Cited by 33 · see citing works

Postoperative Euglycaemic Diabetic Ketoacidosis Associated with Sodium–Glucose Cotransporter-2 Inhibitors (Gliflozins): A Report of Two Cases and Review of the Literature

Chacko, B., Whitley, M., Beckmann, U., Murray, K., & Rowley, M. (2018) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1804600212 · Cited by 32 · see citing works

Sodium-glucose cotransporter-2 inhibitors

Bardia, A., Wai, M., & Fontes, M. L. (2018) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000674 · Cited by 32 · see citing works

Use of sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations

Deerochanawong, C., Chan, S. P., Matawaran, B. J., Sheu, W. H., Chan, J. C. N., Man, N. H., Suastika, K., Khoo, C. M., Yoon, K., Luk, A. O. Y., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13819 · Cited by 30 · see citing works

Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period

Menghoum, N., Oriot, P., & Hermans, M. P. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102275 · Cited by 31 · see citing works

Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering

Neuen, B. L., Cherney, D. Z. I., Jardine, M., & Perkovic, V. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.190047 · Cited by 29 · see citing works

Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis

Rafey, M. F., Butt, A., Coffey, B., Reddington, L., Devitt, A., Lappin, D., & Finucane, F. M. (2019) · Endocrinology, Diabetes &amp; Metabolism Case Reports · doi:10.1530/edm-19-0087 · Cited by 29 · see citing works

Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes

Handelsman, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01054-w · Cited by 29 · see citing works

COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report

Batista, D. V., Vieira, C. A. F. D. A., Costa, T. A., & Lima, E. G. (2020) · Diabetology International · doi:10.1007/s13340-020-00473-3 · Cited by 28 · see citing works

Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects

Kubota, Y., & Shimizu, W. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.03.009 · Cited by 29 · see citing works

Mitigation of cisplatin-induced peripheral neuropathy by canagliflozin in rats

Abdelsameea, A. A., & Kabil, S. L. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1521-5 · Cited by 27 · see citing works

Euglycemic Diabetic Ketoacidosis Due to Sodium–Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy

Pace, D. J., Dukleska, K., Phillips, S. M., Gleason, V. M., & Yeo, C. J. (2018) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2018.0016 · Cited by 27 · see citing works

Ketogenic diets in the management of type 1 diabetes: Safe or safety concern?

Buehler, L. A., Noe, D. R., Knapp, S., Isaacs, D. M., & Pantalone, K. M. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20121 · Cited by 29 · see citing works

A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis

Patel, K., & Nair, A. (2022) · Cureus · doi:10.7759/cureus.29652 · Cited by 26 · see citing works

Safe and pragmatic use of sodium–glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement

Kalra, S., Ghosh, S. K., Aamir, A., Ahmed, M. T., Amin, M. F., Bajaj, S., Baruah, M., Bulugahapitiya, U., Das, A., Giri, M., et al. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.196029 · Cited by 26 · see citing works

Postcardiac Surgery Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Cotransporter 2 Inhibitors

Auerbach, J. S., Gershengorn, H. B., Aljure, O., Lamelas, J., Patel, S. S., Ferreira, T., Gonzalez, L. A., & Cabrera, J. L. (2023) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2023.01.041 · Cited by 25 · see citing works

Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in the perioperative setting

Peacock, S. C., & Lovshin, J. A. (2017) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-017-1019-5 · Cited by 24 · see citing works

Diabetes mellitus in a patient with glycogen storage disease type Ia: a case report

Cohn, A. Y., & Ohri, A. (2017) · Journal of Medical Case Reports · doi:10.1186/s13256-017-1462-5 · Cited by 23 · see citing works

Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy’s safety profile

Schwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 23 · see citing works

Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management

Kum-Nji, J. S., Gosmanov, A. R., Steinberg, H. O., & Dagogo-Jack, S. E. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.11.004 · Cited by 23 · see citing works

Euglycaemic diabetic ketoacidosis in patients using sodium‐glucose co‐transporter 2 inhibitors

Isaacs, M., Tonks, K. T. T., & Greenfield, J. R. (2017) · Internal Medicine Journal · doi:10.1111/imj.13442 · Cited by 23 · see citing works

Association of British Clinical Diabetologists (ABCD) position statement on the risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors

Dashora, U. K., Gallagher, A., Dhatariya, K., Winocour, P. H., & Gregory, R. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.112 · Cited by 11 · see citing works

“The Proof is in the Pudding”: Do SGLT2 Inhibitors Cause Diabetic Ketoacidosis?

Barengolts, E. I. (2017) · AACE Clinical Case Reports · doi:10.4158/accr-2017-0091

Relationship Between Euglycemic Diabetic Ketoacidosis and SGLT-2 Inhibitors

Çelik, M. (2018) · Global Journal of Endocrinological Metabolism · doi:10.31031/gjem.2018.02.000530

Sodium–Glucose Cotransporter 2 Inhibitors and Diabetic Ketoacidosis: A Case Series From Three Academic Institutions

Misaghian-Xanthos, N., Shariff, A. I., Mekala, K. C., Fearrington, L. R., Setji, T. L., Aloi, J., & Buse, J. B. (2017) · Diabetes Care · doi:10.2337/dc16-2591 · Cited by 19 · see citing works

Diabetic ketoacidosis with SGLT2 inhibitors

Musso, G., Saba, F., Cassader, M., & Gambino, R. (2020) · BMJ · doi:10.1136/bmj.m4147 · Cited by 104 · see citing works